EGFR and lung cancer: Mechanisms of resistance to targeted therapy: Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), which target early-stage lung cancer with EGFR mutations, have been among the most successful targeted cancer therapies [175,176,177].